Goldfinch Bio inks $100m Series B

Cambridge, Massachusetts-based Goldfinch Bio, a clinical stage biotechnology company focused on treating kidney diseases, has raised $100 million in Series B financing.

ByIris Dorbian

1 July 2020•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Goldfinch Bio inks $100m Series B

Ally Bridge Group

BlackRock

Irving Investors

Wellington Management

Related articles